View all ESC 2026 trials
Low-Voltage Ablation in Persistent Atrial Fibrillation
Key result
Adjunctive low-voltage zone ablation boosts 12-month atrial arrhythmia freedom by an absolute ~30% vs PVI alone.
- OR 3.5
- 95% CI 2.0-6.2
- P<.001
- n=209
Why the trial?
Pulmonary vein isolation alone frequently fails in persistent atrial fibrillation, and trials of additional substrate ablation have conflicted. IDEAL-AF asked whether individualised ablation of low-voltage areas improves outcomes over standard PVI.
Does adjunctive individualized low-voltage zone ablation improve freedom from atrial arrhythmia in adult patients with persistent atrial fibrillation and significant low-voltage zones undergoing first-time ablation?
Population
209 randomized (of 936 mapped) with persistent AF + low-voltage zones ≥3.0 cm²
Comparison
PVI + individualized low-voltage-zone ablation vs PVI alone
Design
Multicenter randomized clinical trial at 5 Swedish ablation centres
Follow-up
12 months
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Where experts stand
Experts read IDEAL-AF as strong evidence that substrate-guided ablation beyond pulmonary vein isolation alone meaningfully improves outcomes in persistent AF with low-voltage zones, though questions remain about how results compare with other trials.
The reaction is broadly positive: clinicians see the trial as an important step toward individualized, substrate-guided ablation rather than a one-size-fits-all approach. One electrophysiologist flags a striking difference in the control-arm recurrence rates between IDEAL-AF and a similar trial, raising questions about patient selection and generalizability. The live question is whether these findings will shift guidelines toward routine low-voltage zone mapping in persistent AF ablation.
Agreement
Multiple clinicians agree that IDEAL-AF supports moving toward individualized, substrate-guided ablation in persistent AF with low-voltage zones, calling it an important advance over pulmonary vein isolation alone.
2 clinicians say this directly
Still unclear
One researcher highlights that the PVI-alone arm performed far worse in IDEAL-AF than in the comparable SUPPRESS-AF trial, raising questions about whether patient selection or procedural differences explain the gap. It also remains open whether these results will prompt guideline updates recommending routine voltage mapping before persistent AF ablation.
Key expert perspectives
Celebrates the IDEAL-AF publication in JAMA as a proud milestone for the team
Drca highlights the publication of IDEAL-AF in JAMA and celebrates the team behind the trial, signaling confidence in the work's importance.
Distilled from their postX post
MO
Masato Okada · Aug 31 Endpoint critique Flags that the PVI-alone recurrence rate was far higher in IDEAL-AF than in the comparable SUPPRESS-AF trial, questioning what drove the difference. X post
Edgardo Alania · Aug 31 Results readout Calls the results a move toward substrate-guided rather than one-size-fits-all ablation, noting improved arrhythmia-free survival and quality of life without more serious adverse events. X post
Implication
Supports adjunctive low-voltage ablation in persistent AF with significant zones; extends randomized evidence beyond pulmonary vein isolation alone.
Key Points
- To determine whether adding individualized low-voltage zone ablation to pulmonary vein isolation improves arrhythmia freedom and health-related quality of life in persistent atrial fibrillation.
- Multicenter randomized clinical trial conducted at 5 Swedish ablation centers with 12 months of follow-up (ClinicalTrials.gov: NCT04377594).
- Screened 936 adults undergoing first-time ablation and randomized 209 patients with low-voltage zones ≥3.0 cm² to pulmonary vein isolation plus individualized low-voltage zone ablation (n = 102) or isolation alone (n = 107).
- Arrhythmia-free survival at 12 months without antiarrhythmic drugs occurred in 67.6% (69/102) of the combination group versus 37.4% (40/107) of the control group (unadjusted difference 30.3% [95% CI, 17.4%-43.2%]; OR 3.5 [95% CI, 2.0-6.2]; P < .001).
- Time to first arrhythmia recurrence after a single procedure favored the low-voltage ablation group (HR 0.4 [95% CI, 0.3-0.6]; P < .001), with greater improvements in quality of life and similar serious adverse event rates.
Evidence details
What drove the result?
| Outcome | PVI + LVZ | PVI alone |
|---|---|---|
| Freedom from atrial arrhythmia off AADs at 12 months | 69/102 (67.6%) | 40/107 (37.4%) |
| Primary · difference 30.3 pp (95% CI 17.4–43.2); OR 3.5 (2.0–6.2); p<0.001; after 1–2 procedures | ||
| Time to first recurrence after a single procedure | ||
| Secondary · HR 0.4 (95% CI 0.3–0.6; p<0.001) favoring low-voltage-zone ablation | ||
Limitations & tradeoffs
Representation
Applies only to the 22% of screened patients with low-voltage zones ≥3.0 cm² (209 of 936).
Design limitations
The primary endpoint permitted a repeat ablation within 6 months, and serious adverse event rates are described only as similar between groups with no counts reported.
Patient burden
Quality-of-life gains are stated without numeric detail.
Structured PICO
Does adjunctive individualized low-voltage zone ablation improve freedom from atrial arrhythmia in adult patients with persistent atrial fibrillation and significant low-voltage zones undergoing first-time ablation?
P
Population
209 adult patients with persistent atrial fibrillation and low-voltage zones ≥3.0 cm2 undergoing first-time ablation, followed for 12 months.
I
Intervention
Individualized adjunctive low-voltage zone ablation following pulmonary vein isolation (n=102)
C
Comparator
No further ablation following pulmonary vein isolation (n=107)
O
Outcome
Freedom from documented atrial arrhythmia without antiarrhythmic drugs at 12 months after 1 or 2 ablation procedures within 6 monthshard clinical
Main Result
Odds Ratio: 3.5 (95% CI 2–6.2)
Absolute Event Rate: 67.6% vs 37.4%
Absolute Risk Reduction: 30.3%
p-value: p=<.001
Adjunctive low-voltage zone ablation significantly improves 12-month arrhythmia-free survival compared to pulmonary vein isolation alone in patients with persistent atrial fibrillation and significant low-voltage zones.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Nordin et al. (2026) conducted an RCT in Persistent atrial fibrillation (n=209). Individualized adjunctive low-voltage zone ablation vs. No further ablation (pulmonary vein isolation alone) was evaluated on Freedom from documented atrial arrhythmia without antiarrhythmic drugs at 12 months after 1 or 2 ablation procedures within 6 months (OR 3.5, 95% CI 2.0-6.2, p=<.001). Adjunctive low-voltage zone ablation added to pulmonary vein isolation improved freedom from atrial arrhythmia compared to isolation alone (67.6% vs 37.4%; OR 3.5; 95% CI 2.0-6.2; P<.001).